On February 8, 2018 Janssen Research & Development, LLC (Janssen) and Johnson & Johnson (NYSE: JNJ) reported that it will provide a pre-recorded webcast focusing on the Phase 3 SPARTAN data for the investigational compound apalutamide in non-metastatic castration-resistant prostate cancer (Press release, Johnson & Johnson, FEB 8, 2018, View Source [SID1234523840]). The webcast is intended for investors and other interested parties, and will be available beginning at 5:00p.m EST on Thursday, February 8, 2018.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The pre-recorded webcast will feature Peter F. Lebowitz, MD, PhD, Global Therapeutic Area Head, Oncology, Janssen Research & Development, who will recap pivotal Phase 3 apalutamide data, which were featured at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary (ASCO GU) 2018 Cancers Symposium. Dr. Lebowitz will also highlight the company’s prostate cancer strategy and portfolio.

The webcast/podcast can be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com and clicking on "Webcasts/Presentations." The webcast duration is approximately 12 minutes and will be available through the end of April.